tiprankstipranks
Trending News
More News >
C'BON COSMETICS Co., Ltd. (JP:4926)
:4926
Japanese Market

C'BON COSMETICS Co., Ltd. (4926) AI Stock Analysis

Compare
0 Followers

Top Page

JP:4926

C'BON COSMETICS Co., Ltd.

(4926)

Select Model
Select Model
Select Model
Neutral 58 (OpenAI - 5.2)
Rating:58Neutral
Price Target:
¥1,378.00
▲(15.99% Upside)
Action:ReiteratedDate:12/30/25
The score is driven primarily by solid financial stability from a debt-free balance sheet, offset by weak cash flow (negative operating and deeply negative free cash flow). Technicals are neutral-to-mixed, while valuation is reasonable with a moderate dividend yield and mid-range P/E.
Positive Factors
Debt-free balance sheet
Zero financial leverage and a sizable equity cushion materially reduce refinancing and solvency risk, giving management flexibility to absorb shocks, fund strategic initiatives or invest in stores/services without near-term debt pressure—supporting stability over months to years.
High gross margin profile
A ~76% gross margin signals strong unit economics in products, enabling profitable markup and room to absorb sales/marketing or service costs. If management improves operating leverage and sales mix, gross margin supports sustainable margin expansion over the medium term.
Service-driven recurring model
In-person counseling and recurring salon services create customer stickiness and cross-sell opportunities, supporting repeat purchases and stable revenue streams. This service-product integration is a structural advantage in personal care that sustains lifetime value and retention.
Negative Factors
Weak cash generation
Negative operating and free cash flow constrain the company’s ability to self-fund growth, capex or working capital needs, forcing reliance on reserves or financing. Persisting cash deficits heighten execution and liquidity risk and limit strategic optionality over the medium term.
Low and volatile returns on equity
Low ROE reflects weak capital efficiency: the company holds a large equity base but earns minimal returns. This structural inefficiency limits shareholder value creation and suggests difficulty in scaling profitable growth without improving operating performance or reallocating capital.
Earnings volatility / past sizable losses
Historic large losses and inconsistent profitability indicate sensitivity to demand cycles or execution lapses. Such volatility complicates long-term planning, raises reinvestment risk, and means recent profit recovery may not be durable without structural fixes.

C'BON COSMETICS Co., Ltd. (4926) vs. iShares MSCI Japan ETF (EWJ)

C'BON COSMETICS Co., Ltd. Business Overview & Revenue Model

Company DescriptionC'BON COSMETICS Co.,Ltd. manufactures and sells cosmetics, quasi-drugs, and beauty appliance products. It offers various products, such as cleansing, lotion, cream, face wash, serum, and makeup base products. The company was founded in 1966 and is headquartered in Kawasaki, Japan.
How the Company Makes MoneyC'BON COSMETICS primarily generates revenue by selling its cosmetics and skincare products to customers, with sales supported by in-person counseling and recurring customer relationships. A second core revenue stream comes from beauty services (e.g., facial treatments) provided through the company’s salons/stores, which both produce service fees and help drive product purchases. Revenue is therefore tied to (1) product sales volume and mix, and (2) utilization of in-store beauty services that encourage repeat visits and repeat purchases. Specific details on pricing structure, membership/continuity programs, wholesale vs. direct-sales mix, or major external partnerships are null.

C'BON COSMETICS Co., Ltd. Financial Statement Overview

Summary
Balance sheet strength is a key positive (no debt and solid equity cushion), but operating quality is mixed: profitability rebounded in 2025 to positive net and operating income with thin margins, while cash generation is a major weakness with negative operating cash flow and sharply negative free cash flow in 2025.
Income Statement
56
Neutral
Revenue has been broadly stable with a modest rebound in 2025 (+2.76% YoY) after declines in 2023 and a flat 2024. Profitability improved materially in 2025, returning to positive net income (¥136m) and positive operating profit, but margins remain thin (net margin ~1.5%, operating margin ~1.6%), well below the stronger gross margin profile (~76%). Results also show meaningful volatility, with sizable losses in 2020–2021 and again in 2023, suggesting earnings are not yet consistently durable.
Balance Sheet
86
Very Positive
The balance sheet is conservatively positioned with essentially no financial leverage (debt-to-equity near zero and total debt at ¥0 in 2025), which materially reduces refinancing and solvency risk. Equity remains large relative to the asset base (¥5.7bn equity vs. ¥8.5bn assets in 2025), providing a cushion through downturns. The main weakness is low and volatile returns on equity (about 2.4% in 2025 following negative returns in 2023–2024), indicating the company has not been consistently converting its capital base into attractive earnings.
Cash Flow
34
Negative
Cash generation is the key pressure point. Operating cash flow turned negative in 2025 (−¥43m) after being positive in 2024 and 2022, indicating weaker cash conversion despite improved reported earnings. Free cash flow is consistently negative across most years and was sharply negative in 2025 (−¥927m), pointing to heavy cash outflows that are not being self-funded by operations. While free cash flow improved in 2024 versus 2023, the overall pattern suggests elevated ongoing cash needs and higher execution risk if negative free cash flow persists.
BreakdownTTMMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue9.02B8.84B8.50B8.53B9.15B9.10B
Gross Profit6.91B6.74B6.40B6.34B7.10B6.92B
EBITDA455.40M324.45M171.85M126.39M418.05M-679.98M
Net Income252.21M136.27M-26.35M-421.77M44.87M-621.87M
Balance Sheet
Total Assets8.67B8.60B8.81B8.84B9.56B9.56B
Cash, Cash Equivalents and Short-Term Investments2.54B2.65B3.63B3.98B2.80B2.32B
Total Debt0.000.004.24M13.27M22.30M25.20M
Total Liabilities3.00B2.89B3.15B3.13B3.36B1.97B
Stockholders Equity5.67B5.70B5.66B5.71B6.20B7.60B
Cash Flow
Free Cash Flow0.00-926.52M-301.11M-693.60M330.15M-803.08M
Operating Cash Flow0.00-43.16M278.19M-81.47M433.37M-694.00M
Investing Cash Flow0.00-849.16M-581.94M1.35B44.91M161.38M
Financing Cash Flow0.00-90.22M-31.20M-91.29M-6.73M-6.80M

C'BON COSMETICS Co., Ltd. Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price1188.00
Price Trends
50DMA
1300.78
Positive
100DMA
1249.00
Positive
200DMA
1207.63
Positive
Market Momentum
MACD
7.84
Positive
RSI
50.27
Neutral
STOCH
37.39
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4926, the sentiment is Neutral. The current price of 1188 is below the 20-day moving average (MA) of 1340.60, below the 50-day MA of 1300.78, and below the 200-day MA of 1207.63, indicating a neutral trend. The MACD of 7.84 indicates Positive momentum. The RSI at 50.27 is Neutral, neither overbought nor oversold. The STOCH value of 37.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4926.

C'BON COSMETICS Co., Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
68
Neutral
¥2.19B-3.0412.96%
63
Neutral
¥6.81B12.522.38%-0.79%
63
Neutral
¥7.98B-49.922.65%11.87%-31.02%
62
Neutral
$20.33B14.63-3.31%3.23%1.93%-12.26%
60
Neutral
¥6.11B8.181.59%-9.99%-35.06%
58
Neutral
¥5.67B-33.121.68%8.46%
52
Neutral
¥5.41B42.42-19.42%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4926
C'BON COSMETICS Co., Ltd.
1,325.00
150.74
12.84%
JP:4918
Ivy Cosmetics Corporation
386.00
136.00
54.40%
JP:4925
HABA Laboratories, Inc.
1,801.00
-19.87
-1.09%
JP:4929
ADJUVANT HOLDINGS CO., LTD.
760.00
-33.19
-4.18%
JP:4934
Premier Anti-Aging Co., Ltd.
620.00
-250.00
-28.74%
JP:4936
AXXZIA, Inc.
331.00
-137.03
-29.28%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Dec 30, 2025